Type your tag names separated by a space and hit enter




Trade Name(s)

  • Myrbetriq

Ther. Class.
urinary tract antispasmodics

Pharm. Class.
beta-adrenergic agonists


Treatment of symptoms of overactive bladder (OAB) including urge urinary incontinence, urgency, and frequency.


  • Acts as a selective beta-3 adrenergic agonist.
  • Increases bladder capacity by relaxing detusor smooth muscle during storage phase of bladder fill-void cycle.

Therapeutic Effect(s):

Decreased symptoms of OAB.


Absorption: 29–35% absorbed following oral administration.

Distribution: Widely distributed.

Metabolism and Excretion: Extensively metabolized, 6% excreted unchanged in urine (25 mg dose), remainder excreted in urine and feces as metabolites.

Half-life: 50 hr.

TIME/ACTION PROFILE (effects on bladder)

POunknown3.5 hr†24 hr
†Blood level.


Contraindicated in:

  • Hypersensitivity;
  • Severe uncontrolled hypertension;
  • End-stage renal disease or severe hepatic impairment (Child-Pugh Class C);
  • Lactation: Probably enters breast milk and may cause adverse reactions in infant.

Use Cautiously in:

  • Hypertension;
  • Bladder outlet obstruction/concurrent antimuscarics (↑ risk of urinary retention);
  • Concurrent use of antimuscarinics used to treat OAB;
  • OB: Use only if potential maternal benefit outweighs risk to etus;
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

CNS: dizziness, headache

EENT: nasopharyngitis

CV: ↑ BP, tachycardia

GI: constipation, diarrhea, nausea

GU: urinary tract infection


* CAPITALS indicate life-threatening.
Underline indicate most frequent.



  • Acts as a moderate inhibitor of the CYP2D6 enzyme system.
  • May ↑ levels and risk of adverse reactions of drugs metabolized by the the CYP2D6 enzyme system including desipramine, flecainide, metoprolol, propafenone, and thioridazine.
  • May ↑ levels and risk of toxicity with digoxin; use lowest effective level of digoxin/monitor serum levels).


PO: (Adults)25 mg once daily; may be ↑ to 50 mg once daily based on need/tolerance after 8 wk.

Renal Impairment
PO: (Adults)CCr 15–20 mL/min–Dose should not exceed 25 mg/day.Hepatic Impairment
PO: (Adults)Moderate hepatic impairment (Child-Pugh Class B)–Dose should not exceed 25 mg/day.


Extended-release tablets: 25 mg, 50 mg


  • Assess patient for urinary urgency, frequency, and urge incontinence periodically during therapy.
  • Monitor BP prior to starting and periodically during therapy; may cause ↑ BP.
  • Monitor for signs and symptoms of angioedema (swelling of face, lips, tongue and/or larynx). Discontinue mirabegron and treat symptomatically.

Potential Diagnoses


  • PO: Administer without regard to food.
    • Swallow tablets whole with water; do not break, crush, or chew.

Patient/Family Teaching

  • Instruct patient to take mirabegron as directed. If a dose is missed, omit dose and begin taking next day; do not take 2 doses on the same day. Advise patient to read Patient Information sheet prior to starting and with each Rx refill in case of changes.
  • Inform patient that mirabegron may cause an increase in BP. Advise patient to have BP checked periodically during therapy.
  • May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Advise patient to notify health care professional if difficulty emptying bladder occurs.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Decreased urinary frequency, urgency, and urge incontinence.

mirabegron is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Davis’s Drug Guide App + Web powered by Unbound Medicine provides up-to-date information on 5000+ trade name and generic drugs. View on the web or download App to your iPhone, iPad, or Android smartphone or tablet. Davis Drug Guide PDF. Learn more.


Quiring, Courtney, et al. "Mirabegron." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. www.drugguide.com/ddo/view/Davis-Drug-Guide/109776/all/mirabegron.
Quiring C, Sanoski CA, Vallerand AH. Mirabegron. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109776/all/mirabegron. Accessed August 18, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Mirabegron. In Davis's Drug Guide. Available from https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109776/all/mirabegron
Quiring C, Sanoski CA, Vallerand AH. Mirabegron [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 August 18]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109776/all/mirabegron.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - mirabegron ID - 109776 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109776/all/mirabegron PB - F.A. Davis Company ET - 16 DB - Davis's Drug Guide DP - Unbound Medicine ER -